Trientine information Trientine Dihydrochloride has been effectively used in the treatment of Wilson's disease since 1969. Trientine act by chelation or binding of copper, causing its increased urinary excretion. Trientine is indicated especially in patients who are intolerant to D-penicillamine or have clinical feature indicating potential intolerant to D-penicillamine. Trientine has fewer side effects in comparison to D-penicillamine and worsening of neurological symptoms after beginning of treatment appears much less common than with D-penicillamine. Trientine Dihydrochloride 300mg capsule has been licensed by the UK Medicines and Healthcare products Regulatory Agency, the MHRA, and supplied since the 1980’s. Summary of Product Characteristics (SmPC) Trientine Stability Information